Rosetta Genomics Reports Rise in Q1 Revenues and Loss; Suspends Guidance | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics today reported a slight rise in its first-quarter revenues and a 6 percent increase in its net loss year over year.

The microRNA-based diagnostics firm reported total revenues of $27,000 for the three-month period ended March 31, compared to $17,000 for the first quarter of 2009.

Rosetta's net loss for the quarter was $3.6 million, or $.22 per share, compared to $3.4 million, or $.30 per share, for Q1 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.